Takeda presents positive results from phase 3 study of vedolizumab for prevention of intestinal acute graft-versus-host disease (agvhd) in patients undergoing allogeneic hematopoietic stem cell transplantation (allo-hsct)

Osaka, japan & cambridge, mass.--(business wire)--takeda (tse:4502/nyse:tak) today announced late-breaking data from the phase 3 graphite study presented at the 2023 tandem meetings, demonstrating vedolizumab achieved a statistically significant and clinically meaningful improvement in lower gastrointestinal (gi) agvhd-free survival by day 180 after allo-hsct with no relevant differences in safety profile versus placebo.
TAK Ratings Summary
TAK Quant Ranking